Key Words: bicuspid aortic valve ◼ extracellular matrix ◼ GATA proteins ◼ GWAS ◼ MMP9 Sources of Funding, see page 1036 BACKGROUND: Bicuspid aortic valve (BAV), the most common congenital heart defect affecting 1% to 2% of the population, is a major risk factor for premature aortic valve disease and accounts for the majority of valve replacement. The genetic basis and mechanisms of BAV etiology and pathogenesis remain largely undefined.
A ortic valve disease (AVD) is a major cause of morbidity and mortality worldwide and represents a significant health and socioeconomic burden. From 2000 to 2012, hospitalization for AVD increased by 59%, and in 2015, the cost to the healthcare system was estimated at $3.207 billion in the United States alone. 1 Despite intense efforts, the etiology and pathophysiology of AVD remain incompletely elucidated, which impedes the development of effective preventive and therapeutic regimens. At present, surgical approaches, including valve replacement, the second leading cardiac surgery in North America, are the only effective treatment options. Cardiovascular diseases such as atherosclerosis and hypertension, as well as congenital malformations such as bicuspid aortic valve (BAV) and Marfan syndrome, are risk factors for premature valve deterioration and aortopathy. 2 BAV is the most common heart defect, affecting 1% to 2% of the population with a higher male prevalence. It features the presence of 2 usually asymmetrical instead of the normal 3 symmetrical leaflets. Individuals with BAV are at increased risk of valve deterioration and account for the majority of valve replacements, particularly in patients <65 years of age. They are also at increased risk of aortic dilatation and dissection, and many develop serious cardiovascular complications 10 years earlier than individuals with a tricuspid aortic valve (TAV). 2, 3 As such, BAV has the greatest health burden of all other congenital heart diseases. The molecular mechanisms underlying the etiology and pathophysiology of BAV and BAV-related valvulo-aortopathy remain largely undefined. BAV is an autosomal-dominant trait with variable expressivity and incomplete penetrance suggestive of genetic and environmental modifiers. Human genetic studies have provided evidence for linkage of 3 loci, 18q, 5q, and 13q, 4 with BAV with MATRIN3 as the candidate 5q gene. 5 Mutations in NOTCH1 and in GATA5-a regulator of the Notch pathway-have also been identified in some patients with BAV. 6, 7 Loss-offunction mutations in genetically engineered mice confirmed a causal relationship between the Notch1 and Gata5 genes and BAV. 8 However, mutations in these genes account for only a small percentage of human BAV, and the genetic basis for the majority of BAVs remains undetermined.
In addition, we lack mechanistic understanding of BAV pathophysiology. For example, it is unclear why BAV is associated with accelerated valve calcification and deterioration, or with aortopathy. Why different BAV subtypes are associated with different clinical outcomes supports the genetic hypothesis. In human, BAVs are classified according to which leaflets-right (R), left (L), and noncoronary (N)-are fused together. The RL type (right and left leaflet fusion) is the most frequent in human, accounting for 59% of BAV, whereas the RN type accounts for 37%. 9 Retrospective analysis suggests that BAV morphology is of prognostic relevance, with RN BAV being associated with a greater degree of valve dysfunction and a shorter time to valve intervention. 10 ,11 BAV morphology also results in different types of aortopathy and distinct hemodynamics across the ascending aorta. 12 Elucidating the molecular mechanisms underlying BAV-associated aortopathy has been hampered by the paucity of BAV animal models. Gata5-null mice provide a model for RN-type BAV. 8 In the case of RL BAV, an inbred line of Syrian hamsters for which the genetic basis remains unknown is available. 13 Both RL-and RN-type BAVs were reported in mice lacking Jag1 in cardiac cells or Notch1 in endothelial cells; these mice have additional cardiac defects and compromised postnatal survival. 14 We now report that mice heterozygous for a mutated Gata6 allele have highly penetrant RL-type BAV. Mechanistically, defective valve remodeling because of dysregulated extracellular matrix (ECM) degradation and decreased cell death are the underlying cause of BAV formation. In humans, we found that GATA6 transcripts and protein levels are lower in the valves and aorta of individuals with BAV compared with those with TAV and that 3 GATA6 gene variants associate with BAV in a cohort of European ancestry. Together, the data suggest that GATA6 may be a novel BAV-causing gene. The study also provides a well-de-
Clinical Perspective
What Is New?
• Bicuspid aortic valve (BAV) is a major risk factor for premature aortic valve disease but its etiology and pathophysiology remain largely elusive.
• Our data suggest that haploinsufficiency of transcription factor GATA6 leads to BAV.
• Our study characterizes a mouse model (Gata6 +/-) for the most frequent type of BAV in human opening the way for pathophysiological investigations.
• Our results indicate that abnormal differentiation of Secondary heart field myocytes lead to BAV.
What Are the Clinical Implications?
• The identification of a potential new gene associated with BAV is relevant for the elucidation of the genetic basis of human aortic valve disease.
• Studies in Gata6 heterozygote mice suggest a role for genetics in valve deterioration and offer unique tools for the study of BAV-related aortopathy.
• Insight into the cellular and molecular basis of normal and pathological aortic valve development may lead to preventative and therapeutic approaches to valve degeneration.
• The work has implications for the diagnosis and follow up of individuals with aortic valve disease.
METHODS
The data, analytic methods, and study materials will be available to other researchers for purposes of reproducing the results or replicating the procedure on request.
Animals
Mouse handling and experimentation were performed in accordance with institutional guidelines. Protocols were approved by the institutional Animal Care committee. Gata6 heterozygous (Gata6 +/-, C57BL/6) mice were previously described. 15 Cell-specific knockouts were generated by crossing Gata6-floxed mice with mice harboring Cre recombinase. The Tie-cre (C57BL/6)-expressing mouse line was previously described.
8 Wnt1-cre (129S4) and Isl1-cre lines (C57BL/6) were obtained from Jackson Laboratories. Unless otherwise specified, mice were put on regular chow (Harlan 2018). For high-fat diet (HFD) experiment, mice were put on high-fat/high-carb chow for a period of 4 months (Bioserv High Fat/High Carb Diet [F3282, 5 kg box]).
Echocardiography
Transthoracic echocardiography was performed using a visual sonics Vevo 770 ultrasound system with an RMV 707 30-MHz transducer as previously described. 16 M-mode imaging was obtained from mice 150 to 220 days of age (n=11-14 mice per group).
Histology
Mouse tissues were fixed with 4% paraformaldehyde in PBS, paraffin embedded, sectioned at 4-μm intervals, and processed. Masson trichrome, Alcian Blue, and Movat Pentachrome stainings were performed by the histology facility at the University of Ottawa.
Immunohistochemistry and Immunofluorescence
Immunohistochemical studies were performed as described previously. 8, 17 The GATA6 antibody 18 was used at 1/1000 dilution. Goat polyclonal IgG GATA4 (C20) antibody was purchased from Santa Cruz (SC-1237X, dilution 1/600). The following antibodies were purchased from Abcam: Semaphorin3C (ab 135842, dilution 1/350), SOX9 (ab3697, dilution 1/100), Periostin (POSTN) (ab14041, dilution 1/1000), α-smooth muscle actin (ab5694, dilution 1/750), total and cleaved Versican (ab19345 and ab177480, dilution 1/250 each), and Notch intracellular domain (ab8925, dilution 1/500). The anti-phospho-histone H3 (Ser10) antibody was from Millipore (06-570, dilution 1/750). The biotinylated anti-goat IgG and anti-rabbit antibodies were from Vector Laboratories (BA5000) and Jackson (Cederlane) (711-065-152), respectively. Streptavidin-HRP conjugate was from Perkin Elmer (NEL 750000 1EA). Immunofluorescence was carried out using anti-HA (sc-805; Santa Cruz) and Alexa Fluor 546 Goat Anti-Rabbit IgG (A-11035; Life Technologies) at a dilution of 1/500, respectively. Image acquisition was completed using the Zeiss AxioObserver D1 microscope.
Cell Count and Terminal Deoxynucleotidyl Transferase-Mediated dUTP End Labeling
Image J software was used to count the number of mesenchymal and endocardial cells in AV and OFT cushions in 3 different sections of 3 to 4 hearts per genotype. Terminal deoxynucleotidyl transferase-mediated dUTP end labeling assays were carried out using a Apoptag kit according to the manufacturer's instructions (Intergen).
Quantitative Real-Time Polymerase Chain Reaction
Total RNA was isolated from snap-frozen hearts with TRIzol reagent (15596018; Life Technologies) using FastPrep beads (6913-100; MP-Bio). cDNAs were generated using the Omniscript RT kit (205113; Qiagen). Oligonucleotide sequences are available on request.
Luciferase Assay
Transfections were carried out as previously described. 17 Total amount of DNA was maintained constant by adding appropriate amounts of empty DNA vector. The BMP4-Luc and GATA6 constructs were previously described. 17 Full-length matrix metalloproteinases 9 (MMP9)-Luc reporter construct 19 was a kind gift from Professor Wolfgang Eberhardt. Site-directed mutagenesis was used to generate mutant constructs, which were verified by sequencing.
Western Blot and Electrophoretic Mobility Shift Assays
Nuclear and cytoplasmic extracts from AD293 cell line overexpressing GATA6 wild-type (WT) and mutant proteins were used. Anti-HA (sc-805, Santa Cruz), anti-GAPDH (ab8245, Abcam), and anti-Nucleolin (D4C70, 14574, Cell Signaling) were used at a dilution of 1/2000. Secondary antimouse (715-035-151, Jackson) and anti-rabbit (711-035-152, Jackson) antibodies were used at 1/40 000 dilution. DNA-binding activity of GATA6 proteins was assessed using nuclear extracts and the proximal GATA site from the BMP4 and MMP9 promoters as described previously.
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Human Subjects
Written informed consent was received from participants before inclusion in all the studies. The microarray analysis study was approved by the ethics committee of the Institut Universitaire de Cardiologie et de Pneumologie de Québec. The human genetic study was approved by the Partners HealthCare Human Research Committee. The human aorta staining study was approved by the University of Ottawa Heart Institute Research Ethics Board.
Microarray Analysis
Gene expression was obtained from 12 aortic valves in each group and measured with the HumanHT-12 v4 Expression
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BeadChip. BAVs were obtained from male patients who underwent aortic valve replacement surgery. Normal TAVs were obtained from male patients who underwent heart transplantation. Gene expression differences between groups of valves were tested using t test.
Human Aorta Staining
Patients from the University of Ottawa Heart Institute undergoing surgical intervention for aortic valve or aortic disease were included in this study. Aortic wall tissue specimens were obtained and fixed for 24 hours in 10% buffered formalin. Six sections were taken horizontally across the excised aortic segment and paraffin embedded; 5-µm sections were prepared.
Human Genetic Studies
A total of 480 white BAV cases genotyped with the Omni2.5 chip were used, yielding 2 379 855 genetic markers from BAVConsortium database, and 2477 white controls genotyped using the HumanOmni5.0 bead chip, with 4 271 233 genetic markers from dbGaP (FHS*). Quality control of the genotype data from both cohorts was performed using Genome Studio and PLINK ( Figure I in the online-only Data Supplement). We considered markers with an MAF >1% and performed extensive principal components-based filtering for population stratification. After merging cases and controls and further quality control, we used 452 BAV cases and 1849 white controls with a common set of 1 355 128 single-nucleotide polymorphisms.
An additive logistic regression model was performed for association analysis adjusted for sex and race using PLINK.
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Statistics
For echocardiography and gene expression analysis, values are presented as means± SEM. P values were generated using Student's 2-tailed t test. For statistical analysis of phenotypegenotype association, the Fisher exact test (2×2 contingency table) was used. For luciferase assay, statistical analysis was done by 1-way ANOVA, followed by Dunnett's multiple comparison post hoc analysis. In all cases, P values <0.05 were considered an index of statistical significance.
RESULTS
Gata6 Haploinsufficiency Leads to RLType BAV
Previously, we reported that transcription factor Gata5 is involved in valvulogenesis and that its loss leads to BAV. 8 Genetic studies aimed at determining modifiers of Gata5 revealed a strong interaction with Gata6. Whereas Gata5 heterozygous mice have no detectable cardiac phenotype, Gata5 +/-Gata6 +/-compound heterozygous embryos have disrupted valvulogenesis and die perinatally because of severe defects in outflow track (OFT) formation. 15 Similarly, Gata4
mice die embryonically at E13.5 because of vascular and OFT defects. 21 Functional cardiac analysis of adult Gata6 heterozygous mice using echocardiography revealed a significant decrease in fractional shortening versus their control littermates ( Figure 1A ). In addition, a large percentage of Gata6 +/-mice had a significantly elevated aortic valve gradient-with no changes in the aortic root diameter-suggestive of AVD ( Figure 1B  through 1D) . Consistent with the presence of cardiac stress, qRT-PCR performed on adult ventricular tissues revealed increased levels of stress markers (ANF, HIF1α) and cardiac remodeling genes (FGFR1/3, CTGF) and decreased levels of sarcoplasmic calcium-ATPase. GATA4 levels were unchanged ( Figure 1E) BAV is a risk factor for premature AVD, including valve calcification and sclerosis (presence of accelerated fibrosis). To determine whether Gata6 +/-are prone to AVD, we analyzed adult Ao valves using Masson trichrome staining, which revealed increased total collagen content in some Gata6 +/-BAV and TAV, indicative of valve sclerosis ( Figure 2B ). We also analyzed the levels of several transcripts in dissected aortic valves. As shown in Figure 2C , significant gene expression changes were noted in Gata6 +/-valves, including decreased levels of tissue inhibitor of metalloproteinase 1, fibrillin 1, and VCAN (Versican). These changes are consistent with altered ECM integrity and valve elasticity. The reduced level of SOX9 transcripts in Gata6 +/-valves is also ORIGINAL RESEARCH ARTICLE noteworthy because the decreased expression of SOX9 promotes heart valve calcification ( Figure 2D , a and b). 22 Similarly, decreased levels of POSTN causes derepression of the osteogenic potential of the mesenchymal cells within the OFT and calcium deposition within the aortic valve. 23 Immunohistochemistry showed that expression of POSTN is downregulated in Gata6 +/-valves compared with WT littermates ( Figure 2E , a through c). It is interesting to note that levels of SOX9 and POSTN were differentially regulated in mice fed a normal or HFD. In Gata6 +/+ valves, SOX9 levels were increased in mice on the HFD, whereas POSTN levels were de- 
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creased. In contrast, POSTN levels were upregulated in Gata6 +/-mice on HFD, and SOX9 levels remained unchanged ( Figure 2D and 2E, Lower). Thus, Gata6 haploinsufficiency promotes a proosteogenic state in the aortic valves and disrupts genetic reprogramming in response to proosteogenic stimuli.
Abnormal ECM and Valve Remodeling Underlie GATA6-Dependent BAV
Defects in epithelial to mesenchymal transformation, a critical stage during valvulogenesis, can lead to BAV. 24 To determine whether cell number and composition of the OFT cushions are changed in Gata6 ORIGINAL RESEARCH ARTICLE similar SEMA3C expression pattern at the level of the cells surrounding the branchial arch arteries and in the left lateral wall of the conus in E11-11.5 from both genotypes ( Figure IE in the online-only Data Supplement, Left). These results suggest that the defect observed in Gata6 +/-is not because of defective CNCC migration to the OFT cushions. Thus, the formation of BAV in Gata6 +/-does not appear to be caused by defective cell proliferation, migration, or differentiation processes.
Abnormal septation and valve thickening could be the result of either excessive proliferation in the valves or defective remodeling, which involves cell apopto- It is important to note the significant decrease in the expression of matrix metalloprotease 9 (MMP9), BMP4, and GATA6 (corrected to RPS16, n=5-8 per group). E, Schematic representation of GATA sites on the MMP9 promoter. pGL3-MMP9-One GATA site is a 5' deletion, leaving only 1 GATA site, and p-GL3-MMP9-No GATA site promoter has a mutation in this site. Increasing amounts of GATA6 expression vector are transiently cotransfected with the indicated luciferase reporters in NIH3T3 cells (25, 50 , 100, 250, and 500 ng of expression vector). Relative luciferase activities are represented as fold changes. The data are representative of 3 independent experiments done in duplicates.*P<0.05.
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sis. Valve remodeling was examined in transverse sections of E14.5 embryos using terminal deoxynucleotidyl transferase-mediated dUTP end labeling or phosphohistone H3 staining. As shown in Figure 3A and 3B, cell death was significantly lower in Gata6 +/-valves, whereas cell proliferation was modestly increased. This result suggests abnormal apoptosis and valve remodeling in Gata6 +/-mice, which could result from an abnormal synthesis or breakdown of the ECM, a regulator of cell survival, migration, and proliferation. 26 MMPs and their endogenous inhibitors, tissue inhibitors of MMPs, play an important role in the ECM degradation process. Expression of mRNA levels of MMP9, tissue inhibitor of MMP1, MMP2, and tissue inhibitor of MMP2 was assessed in Gata6 +/-E11.5 hearts. At this stage, a significant decrease in MMP9 levels along with a trend of decrease in MMP2 was observed ( Figure 3D ), which could lead to dysregulated ECM degradation. Consistent with this finding, immunohistochemistry revealed lower levels of cleaved versican in E14.5 Gata6 +/-valves ( Figure 3C ). Expression of genes known to be involved in OFT formation and valve remodeling was also examined. BMP4, a direct target for GATA6, whose deletion from the anterior heart field alters OFT septation, 18, 27 was significantly decreased (48%) in Gata6 +/-hearts ( Figure 3D ). We tested whether MMP9 is transcriptionally regulated by GATA6. In silico analysis of the MMP9 promoter revealed the presence of conserved GATA-binding sites ( Figure 3E ). Cotransfection in NIH3T3 cells of GATA6 expressing vector and MMP9 luciferase constructs showed significant GATA6 activation of the MMP9 promoter that is dependent on the presence of the proximal GATA site (Figures 3E and 4B) . Mutations in human GATA6 have been reported in congenital heart disease associated with OFT defects ( Figure 4A and Table I in the online-only Data Supplement). 28 The second zinc finger in GATA6 mediates most protein-protein interactions as well as binding to DNA, and it is the site of many human mutations. We examined the effect of several GATA6 mutant proteins on transcriptional activation. All mutants showed reduced transcriptional activation of MMP9 and BMP4 promoters ( Figure 4B and data not shown). It is interesting to note that most mutations (except for T452A) showed reduced nuclear Additionally, all GATA6 mutants tested were unable to bind GATA elements ( Figure IIC in the online-only Data Supplement). The results suggest that functional GATA6 haploinsufficiency resulting from these mutations may cause human coronary heart disease.
Loss of 1 Gata6 Allele in Isl1+ Cells Recapitulates the Aortic Valve Phenotype of Gata6 Heterozygous Mice
Endothelial, neural crest, and secondary heart field (SHF) myocytes contribute to OFT formation. Endothelial cells within and lining the interior of the OFT vessels undergo epithelial to mesenchymal transformation, giving rise to the endocardial cushions. 29 CNCCs that arise from the dorsal neural tube and migrate as mesenchymal cells to populate the OFT are known to contribute to the formation of the endocardial cushion and the septum separating the aortic and pulmonary trunks. 30 Recent studies have suggested that SHF precursors lying in the ventral pharynx are able to interact with CNCC migrating to the OFT cushion; together they control ECM development and apoptosis during valve remodeling. 31 Later on, invading CNCCs merge with the endocardial cushion cells and SHF mesenchymal cells to ensure the elongation and proper septation of the OFT. Because GATA6 is present in all these lineages, 18 
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as assessed by the Fisher exact test (P=0.0021). Thus, GATA6 appears to be essential in SHF cells for proper aortic valve formation.
GATA6 Expression and Variants in Human BAV
We investigated whether variants within the GATA6 gene associate with human BAV using 452 sporadic BAV cases and 1849 controls. After quality control (detailed in Figure III in the online-only Data Supplement), an additive logistic regression model revealed nominal association of several variants (Figure 6A and 6B and  Tables II and III in the online-only Data Supplement) . However, none reached the locus wide significance (0.00014). We also analyzed GATA6 expression in human tissues of individuals with BAV and TAV. In human aortic valve tissues, GATA6 transcripts were significantly lower in the BAV versus TAV specimens ( Figure 6C and Table IV in the online-only Data Supplement). Similarly, GATA6 immunoreactivity was lower in aortic tissue sections from patients with BAV versus TAV who underwent aortic repair surgery ( Figure 6D and Table V in the online-only Data Supplement). It is interesting to note that this decrease was more pronounced in tissues from patients with RL-versus RN-type BAV. Immunostaining for activated Notch intracellular domain and smooth muscle actin were used as controls. Together, the data suggest a potential role for GATA6 in human aortic valve disease.
DISCUSSION
Bicuspid aortic valve is the most common congenital heart defect in humans and a risk factor for aortic valve disease. The genetic basis of BAV formation and aortopathy in the majority of individuals remains unknown. The data presented identify GATA6 as a potential BAV-causing gene and offer a unique animal model to study the pathogenesis of the most frequent type of human BAV.
GATA6 Regulation of Aortic Valve Formation
BAV is a genetically heterogeneous defect. Mutations in GATA5 and NOTCH1 have been reported in some patients with BAV. In addition, 5 distinct loci on human chromosomes 5q, 9q, 13q, 17q, and 18q have been associated with BAV in families. 4, 34, 35 MATR3, the gene encoding MATRIN3, is located on 5q; it is reportedly linked to human BAV, and its deletion in mice leads to partially penetrant BAV. 5 The identity of the causative genes within the other linked loci remains undetermined. The GATA6 gene is located on 18q11.2, and mutations in GATA6 as well as a microdeletion including GATA6 have been reported in patients with congenital heart disease. 36, 37 The present study shows that GATA6 expression is decreased in the valves and aortas of individuals with BAV versus TAV. In the present study, we did not find any common (MAF >1%) variants at the GATA6 locus associated with BAV after accounting for multiple testing. Further studies using whole-exome sequencing or targeted gene sequencing would be required to determine whether there are rare mutations in the GATA6 gene associated with BAV.
GATA6 belongs to the GATA family of zinc finger transcription factors and is predominantly expressed in the heart and gut. 18 Its role within the heart is not fully elucidated and often overlaps with that of another GATA protein, GATA4. Gata6-null mice are embryonic lethal at implantation, but cell-specific loss of Gata6 from myocytes, smooth muscle, or neural crest cells affects cell proliferation and hypertrophic growth and is associated with structural cardiac defects. 38, 39 No gross defects were reported in Gata6 heterozygote mice. The data presented unravel a new role for GATA6 in aortic valve formation and point to its essential function in SHF-derived cells therein. Loss of 1 Gata6 allele from Isl-1+ cells recapitulates the highly penetrant BAV and thickened valve phenotypes seen in Gata6 heterozygote mice. Both phenotypes reflect remodeling defects caused, at least in part, by changes in ECM degradation and dysregulated cellular apoptosis. These can result from decreased levels of GATA6-regulated genes, such as BMP4 and MMP9. BMP4 is a known GATA6 target, 18 and this study identifies MMP9 as a new GATA6 downstream target.
Regulation of ECM plays an important role in normal and pathogenic development and is a key feature of many diseases, such as congenital heart disease, cancer, and inflammatory disorders. It is interesting to note that in colorectal cancers, GATA6 expression correlates with increased invasion and metastasis, whereas in vitro gain and loss of function indicate that GATA6 levels regulate cell migration and invasion. 40 Human GATA6 mutations have been reported in a wide spectrum of coronary heart disease (atrial septal defect, ventricular septal defect [VSD], patent ductus arteriosus, persistent truncus arteriosus, Tetralogy of Fallot), all of which implicate defective ECM because of alteration in the expression of several MMPs. For example, increased MMP2 and MMP9 activities were linked with the pathogenesis of VSD in 96 children with perimembranous VSD. 41 Similarly, loss of MMP Tolloid-like leads to incomplete formation of the interventricular septum in Tll-1 knockout mice. An insertion mutation in the exon 10 of Tolloid-like was found in patients with atrial septal defect, VSD, and patent ductus arteriosus. 42 Another MMP, CCN1, plays a role in heart development because Ccn1-null mice have impaired cardiac valvuloseptal morphogenesis resulting in severe atrio-VSD; impaired gelatinase activity and apoptosis may underlie the phenotype. 43 It is now well established that MMPs regulate cell survival, proliferation, and differentiation as well as cell adhesion and migration. More specifically, it is reported that MMP9 can lead to increased apoptosis during development. In fact, Mmp9-null mice display a delay in hypertrophic chondrocyte apoptosis in addition to delayed vascularization and ossification. 44 Together with our findings, this raises the intriguing possibility for a broader role for GATA6 as an ECM regulator in development and disease.
Development of an Animal Model of RLType BAV
BAV is a major risk for premature onset of potentially fatal aortic disease. The heterogeneity of BAV and associated aortopathy combined with the paucity of corresponding animal models constitute a formidable
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challenge for the development of predictive tools for patient management. Identifying patients who could benefit from prophylactic reparative surgery or other interventions is presently an unachieved goal. Evidence is mounting that BAV aortopathy is not similar to that of genetic connective tissue disorders, such as Marfan syndrome, yet the clinical guidelines for BAV are extrapolated from those of Marfan syndrome, in which the molecular mechanisms of disease are well delineated. 45 Recent reviews of knowledge gaps have emphasized the critical need to decipher the molecular pathology of BAV to identify markers of complications and targets for therapies. 2 As mentioned earlier, few mouse models of BAV have been reported, and in most cases the BAV orientation is exclusively RN (Gata5 -/-and Nos3 -/-mice). 8, 46 Loss of the Notch ligand Jag1 from cardiac cells results in a polyvalvular phenotype with 47% BAV of both RN and RL orientations. These mice have VSD and significantly reduced late gestational/perinatal viability. 14 The development of an animal model of RL-type BAV, the most common type in humans, represents a step forward toward understanding the etiology and pathophysiology of BAV, including the role of genetics in BAV-associated aortopathy. Among others, the presence of BAV in only 50% of Gata6 +/-mice will make it possible to address the unanswered question of the contribution of genetics versus hemodynamics to BAV aortopathy and ultimately to developing much needed biomarkers. Indeed, the influence of cusp orientation on the three-dimensional flow patterns across the ascending aorta remains controversial, 12 and genetically controlled studies in human patients have proved challenging. Similarly, retrospective analyses have associated valve configuration with distinct aortopathy risks and long-term outcome of BAV repair. 47 However, the lack of molecular knowledge prevents the development of much needed predictive tools.
In humans, BAV is twice as common in males as in females, but the reason for this sex bias is unclear. It is remarkable that the prevalence of BAV is greater in male Gata6 +/-mice versus female mice. BAV presentation is also heterogeneous in humans even within each subtype (RL, RN, and LN). Variations include presence/ absence of raphe and leaflet thickness and size. This heterogeneity is also observed in the Gata6 +/-mice, with variable valve thickness and functionality. The availability of a mouse model that faithfully recapitulates features of the human disease will help unravel the genetic and environmental modifiers of BAV and BAV aortopathy. For example, the work presented indicates profound gene expression changes in BAV as well as TAV from Gata6 +/-mice ( Figure 2) . In both cases, we observed increased evidence of sclerosis as well as increased markers of the proosteogenic program. In addition, gene expression changes in response to a proinflammatory/procalcific stimulus (HFD) were disrupted in Gata6 +/-mice irrespective of the valve orientation. Together, these observations suggest that genetics may play a critical role in the progression of aortic valve disease. The availability of mice with bicuspid or tricuspid aortic valves on the same genetic background opens the way for molecular dissection of the etiology and pathophysiology of aortic valve disease, which will ultimately result in the identification of biomarkers and therapeutic targets.
